Lp(a) measurement in clinical practice is infrequent even among patients with atherosclerotic cardiovascular disease (ASCVD), though there are signs that testing is becoming more common and that it can lead to increased use of lipid lowering therapies (LLT), according to results of two large US studies.1,2
Educational Partners and Supporters
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
(Founding Partner)